Nymox Pharmaceutical Corporation
OTC: NYMXF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul Averback
- Employees
- 16
- Headquarters
- Nassau, Bahamas
- IPO year
- 1997
- Market cap
- $10.4M
- Website
- https://nymox.com
Loading NYMXF…
Loading profile data…Frequently asked questions about NYMXF
What does Nymox Pharmaceutical Corporation (NYMXF) do?
Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinic...
Where does NYMXF trade?
Nymox Pharmaceutical Corporation (NYMXF) trades on the Other OTC.
What sector is NYMXF in?
Nymox Pharmaceutical Corporation (NYMXF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nymox Pharmaceutical Corporation?
Paul Averback is the chief executive officer of Nymox Pharmaceutical Corporation (NYMXF).
Where is Nymox Pharmaceutical Corporation headquartered?
Nymox Pharmaceutical Corporation is headquartered in Bahamas.
Does NYMXF pay a dividend?
Nymox Pharmaceutical Corporation (NYMXF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NYMXF go public?
Nymox Pharmaceutical Corporation (NYMXF) completed its initial public offering in 1997.